Abstract

Febuxostat and allopurinol are xanthine oxidase inhibitors to reduce uric acid levels. The research aimed to determine the differences in efficacy and safety of using febuxostat and allopurinol for gout patients. This research was conducted using a narrative review method for articles obtained from the PubMed and Willey databases published in 2010-2021. From the article exploration, 5 articles were reviewed showing that the determination of drug efficacy was seen by monitoring the changes in uric acid levels for 6 months from the beginning of drug use. Febuxostat and allopurinol had good efficacy in achieving target uric acid levels < 6 mg/dL, however, febuxostat was superior to allopurinol in usual doses. Febuxostat 80 mg had superior efficacy to febuxostat 40 mg, while febuxostat 40 mg had superior efficacy to allopurinol 300 mg (p < 0.05). For safety, febuxostat and allopurinol possessed similar side effects in the form of upper respiratory tract infection, diarrhea, headache, nausea and vomiting.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.